Fennec Pharmaceuticals (FENC) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order, formal legal business addressed, and agenda outlined, including business updates and Q&A session.

• Notice of meeting and proxy materials delivered to shareholders as required.

• Quorum confirmed and meeting declared properly constituted for business transactions.

Financial performance review

• Record net product sales achieved in 2025, with significant growth in the Fennec HEARS patient support program.

• Strengthened financial position through a $42 million equity offering and full debt redemption.

• Q1 2026 net product sales reached $15.1 million, up 73% year-over-year from Q1 2025.

• Six consecutive quarters of strong performance, with record patient enrollments and highest demand month in April 2026.

Board and executive committee updates

• Five directors nominated and elected: Khalid Islam, Chris Rallis, Marco Brughera, Jodi Cook, and Jeff Hackman.